Enantioselective organocatalytic construction of pyrroloindolines by a cascade addition–cyclization strategy: Synthesis of (-)-flustramine B by Austin, Joel F. et al.
Enantioselective organocatalytic construction of
pyrroloindolines by a cascade addition–cyclization
strategy: Synthesis of ()-flustramine B
Joel F. Austin, Sung-Gon Kim, Christopher J. Sinz, Wen-Jing Xiao, and David W. C. MacMillan*
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125
Edited by Jack Halpern, University of Chicago, Chicago, IL, and approved February 23, 2004 (received for review December 12, 2003)
Pyrroloindoline and bispyrroloindoline are a subclass of alkaloid
structural motifs that commonly exhibit biological activity. An
enantioselective organocatalytic approach to the synthesis of pyr-
roloindoline architecture is described. The addition–cyclization of
tryptamines with ,-unsaturated aldehydes in the presence of
imidazolidinone catalysts 1 and 8 provides pyrroloindoline adducts
in high yield and excellent enantioselectivities. This transformation
is successful for a wide range of tryptamine and ,-unsaturated
aldehyde substrates. This amine-catalyzed sequence has been
extended to the enantioselective construction of furanoindoline
frameworks. Application of this pyrroloindoline-forming reaction
to natural product synthesis has been accomplished in the context
of the enantioselective synthesis of ()-flustramine B.
The pyrroloindolines and bis-pyrroloindolines represent adiverse family of structurally complex polyindoline alkaloids
that have been isolated from a widespread series of natural
sources (1), including amphibians, plants, and marine algae (Fig.
1). First described in the late 1930s, this alkaloid family has been
found to exhibit remarkable biological properties across a broad
spectrum of pharmacological screens. For example, several
alkaloids isolated from fungal sources that comprise the C(3a)-
bispyrroloindoline–diketopiperazine architecture have been
shown to be powerful antagonists of cholecystokinin, substance
P, and neurokinin 1 receptors (2–4). A related family of alkaloids
that incorporates polythioketopiperazines has also been estab-
lished to exhibit potent anticancer activities against lymphocytic
leukemia cell lines (5) and cytotoxicity to HeLa cell lines (6).
Furthermore, McAlpine and coworkers (7–9) have reported
that the pyrroloindoline 5-N-acetylardeemin demonstrates the
ability to restore vinblastine sensitivity to tumor cell lines that
manifest ‘‘operational resistance’’ to cytotoxic agents. The hy-
droxypyrroloindoline gypsetin has evoked interest as a potential
inhibitor of the enzyme acyl-CoA:cholesterol acyltransferase
and as such might find therapeutic use as a cholesterol-lowering
agent (10–12). Psycholeine and quadrigemine C have been
documented as the first nonpeptide antagonists of the soma-
tostatin family of receptors (13). Several other polyindolines in
this natural product family have also been shown to exhibit
significant biological properties (13, 14–40).
A structural survey of this alkaloid family reveals a central
cis-fused pyrroloindoline core that in all cases incorporates a
quaternary center at the C(3a) site. A challenging structural
feature with regard to developing a general strategy, the C(3a)
position has been shown to incorporate broad variation in
substituents and stereogenicity. For example, whereas pseu-
dophrynamine A and flustramine B are found to incorporate an
unsubstituted methylene at C(3a), urochordamine exhibits a
tertiary carbon stereocenter at this site, whereas amauromine
and chimonanthine contain vicinal fully substituted carbons
between the C(3a)–C(3a) positions. Indeed, chimonanthine
presents a formidable synthetic challenge in the form of a vicinal
quaternary carbon diastereochemical relationship.
The structural complexity of the pyrroloindolines makes them
a particularly elusive and, at the same time, appealing target for
total synthetic efforts. In this regard the Overman and Dan-
ishefsky groups have made seminal contributions in their design
of new reaction methods that have enabled the rapid construc-
tion of many of these complex alkaloids. The Overman group has
focused on the development of bis-Heck technology for the
diastereoselective construction of a bisoxindole that is subse-
quently converted into the bispyrroloindoline core (41, 42). This
highly innovative technology efficiently utilizes the stereochem-
ical information of a conformationally locked cyclohexene sub-
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Fig. 1. Representative pyrroloindoline natural isolates.
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strate to generate the requisite vicinal C(3a)–C(3a) quaternary
carbon relationship. Link and Overman (43) have also reported
a bis-enolate alkylation approach to bispyrroloindoline contain-
ing natural products. The Danishefsky group has used enantio-
pure tryptophan-based starting materials for their asymmetric
synthesis of amauromine and the ardeemins (44, 45). Their
strategy relies on stereochemical induction from a resident
stereocenter derived from tryptophan in a cascade selenation–
ring-closing protocol. The selenato functionality is then used in
an ingenious radical addition step to introduce the ‘‘reverse
prenyl’’ group as exhibited in amauromine. Both of these strat-
egies are elegant, creative, and highly effective solutions to the
construction of pyrroloindoline architecture. With these elegant
approaches in mind, we sought to develop a complementary
technology that would allow the enantioselective catalytic con-
struction of pyrroloindoline architecture in one step with con-
comitant stereocontrolled generation of the requisite C(3a) and
vicinal C(3a) stereogenicity.
Methods
Iminium Catalysis. Our laboratory has recently disclosed (46–54)
a strategy for asymmetric synthesis based on the capacity of
chiral amines to function as enantioselective catalysts for a range
of transformations that traditionally use Lewis acids. This ca-
talysis concept was founded on the mechanistic hypothesis that
the reversible formation of iminium ions from ,-unsaturated
aldehydes and amines (Scheme 2) might emulate the equilibrium
dynamics and -orbital electronics that are inherent to Lewis
acid catalysis (Scheme 1). This new catalysis strategy has sub-
sequently been applied to the development of a variety of
enantioselective chemical processes, including cycloadditions
(46, 47, 50), Mukaiyama–Michael additions (53), Friedel–Crafts
alkylations (48, 49, 52), heteroconjugate additions, hydrogena-
tions, and cascade reactions.
Central to these studies, we have identified a simple cyclic
amine 1 that performs as a highly effective asymmetric catalyst
for a broad range of new and traditional chemical transforma-
tions. The development of amine catalyst 1 was made on the basis
of two design objectives, the requirement for (i) iminium ion
geometry control and (ii) high levels of enantiofacial discrimi-
nation. As shown by the computational model MM3-2 (Fig. 2),
the catalyst-activated iminium ion 2 was expected to be formed
with (E)-isomer selectivity to avoid nonbonding interactions
between the substrate olefin and the bulky tert-butyl group. In
terms of enantiofacial discrimination, the calculated iminium
structure MM3-2 also reveals that the benzyl and tert-butyl
groups on the catalyst framework will effectively shield the
Si-face of the substrate, leaving the Re-face exposed for enan-
tioselective bond formation.
Pyrroloindoline Construction. In recent studies we have established
the utility of lowest unoccupied molecular orbital-lowering
iminium catalysis as a valuable platform for the development of
enantioselective Friedel–Crafts alkylations by using anilines
(52), pyrroles (48), oxazoles, furans, and thiophenes. Inclusive to
this research, we have also demonstrated that the conjugate
addition of indole substrates to ,-unsaturated aldehydes can
be achieved with excellent levels of enantiocontrol (Scheme 3)
(49). Based on a variety of mechanistic considerations, we sought
to explore whether this indole addition pathway might be
manipulated to allow the cascade formation of pyrroloindoline
architecture in lieu of substituted indole production (Scheme 4).
As elaborated in Fig. 3, we envisioned that the addition of an
indole derived from tryptamine 4 to the activated iminium ion
3 (arising from catalyst 1 and an ,-unsaturated aldehyde)
would generate the C(3)-quaternary carbon-substituted indo-
lium ion 5. As a central design feature, this quaternary carbon-
bearing indolium cannot undergo rearomatization by means of
proton loss in contrast to the analogous 3-H indole addition
Schemes 1 and 2.
Scheme 3.
Scheme 4.
Fig. 2. Iminium catalysis concept: Imidazolidinone catalyst and correspond-
ing iminium structure. Fig. 3. Pyrroloindoline formation: Catalytic cycle.
Austin et al. PNAS  April 13, 2004  vol. 101  no. 15  5483
CH
EM
IS
TR
Y
SP
EC
IA
L
FE
A
TU
RE
pathway. As a result, we expected the prevailing reaction path-
way to be partitioned toward a 5-exo-heterocyclization of the
pendant ethylamine, thereby generating the tricyclic system 6.
Subsequent hydrolysis of the tethered enamine moiety would
provide the requisite pyrroloindoline framework and, in doing
so, would reconstitute the imidazolidinone catalyst. In terms of
molecular complexity development, this cascade sequence
should allow the rapid and enantioenriched formation of ste-
reochemically defined pyrroloindoline architecture from
tryptamines and simple ,-unsaturated aldehydes. Moreover,
we hoped that the requisite C(3a) quaternary carbon would be
forged with high levels of enantio- and diastereocontrol by using
a simple amine catalyst.
Supporting Information. Experimental procedures, structural
proofs, and spectral data for all new compounds are provided as
supporting information on the PNAS web site.
Results
Our enantioselective organocatalytic pyrroloindoline construc-
tion was first evaluated by using N(10)-t-butoxycarbonyl (BOC)-
N(1)-allyltryptamine with acrolein and a series of imidazolidi-
none catalysts (Table 1). In accord with our mechanistic
postulate, we were delighted to find that the imidazolidinone
catalysts 1a–d provided the desired pyrroloindoline architecture
in good yield (entries 2–8). Although useful levels of enantio-
selectivity could be observed in this addition–cyclization se-
quence [entry 7, 84% enantiomeric excess (ee)], we were sur-
prised to find large variations in enantioinduction as a function
of reaction solvent. As delineated in Table 1, the use of high
dielectric media (e.g., MeOH) led to the predominant formation
of the (3aS)-pyrroloindoline enantiomer (entry 1, () 77% ee),
whereas the use of low dielectric solvents provided the (3aR)-
pyrroloindoline as the major antipode (entry 7, () 84% ee).
Although reaction media are known to influence a variety of
stereoselective processes, this apparent correlation between
solvent dielectric and the magnitude of change in the absolute
sense of enantiofacial discrimination is, to our knowledge,
without precedent. The tryptophan-derived imidazolidinone salt
8a was found to exhibit the optimal levels of enantioinduction in
the addition to acrolein in the presence of CH2Cl2–H2O. This
increase in selectivity is postulated to arise from the more
efficient stabilization by catalyst 8 of the ,-unsaturated imi-
nium ion by means of a favorable cation– interaction. The
superior levels of asymmetric induction and reaction efficiency
exhibited by the trif luoroacetyl salt 8a to afford the pyrroloin-
doline (3aS)-10 in 89% ee and 85% yield prompted us to select
this catalyst for further exploration.
Experiments that probe the scope of the tryptamine N(1) and
N(10) substituents are summarized in Table 2. The reaction
appears quite tolerant with respect to the steric contribution of
the N(10) carbamate substituent (R  Et, allyl t-Bu, entries 1–5,
82% yield, 89–90% ee). As revealed in entries 2–5, the reaction
can also accommodate a variety of electron donating N(1)-indole
substituents (entry 2, N-allyl, 89% ee; entry 3, N-prenyl, 89% ee;
entry 5, N-Bn, 90% ee). To demonstrate the preparative utility,
the addition of N (10)-BOC-N (1)-benzyltryptamine to acrolein
was performed on a 2 mmol scale with catalyst 8a to afford the
corresponding pyrroloindoline (entry 5) in 90% ee and 82%
yield.
Table 1. Effect of cocatalyst and solvent on the organocatalytic pyrroloindoline construction
Entry Solvent Dielectric Catalyst Yield, % []D ee, *%
1 MeOH† 32.6 1c 9 () 77‡
2 MeOH§ 32.6 1d 64 () 69¶
3 Acetone§ 20.2 1d 58 () 60¶
4 DME§ 5.0 1d 18 () 21¶
5 CHCI3§ 4.8 1d 66 () 45¶
6 Toluene§ 2.4 1d 60 () 59¶
7 Toluene 2.4 1b 50 () 84**
8 CH2Cl2†† 9.1 1a 79 () 70‡
9 CH2Cl2†† 9.1 8a 85 () 89‡
p-TSA, para-toluenesulfonic acid; DME, 1,2-dimethoxyethane.
*Product ratios determined by HPLC.
†With no H2O.
‡Reaction performed at 85°C.
§SolventH2O  90:10.
¶Reaction performed at 40°C.
SolventH2O  98:2.
**Reaction performed at 4°C.
††SolventH2O  85:15.
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We next examined the utility of -substituted ,-
unsaturated aldehydes in this enantioselective pyrroloindoline
formation. The principal issue in this reaction is that of
absolute and relative stereocontrol in the construction of the
vicinal C(3a)–C(3a) stereocenters. As revealed in Table 3,
significant variation in the steric contribution of the olefin
substituent (X  CO2Me, CH2OR, COPh), entries 1–3) is
possible without loss in yield or enantiocontrol (66–93% yield,
91–94% ee). From the perspective of pyrroloindoline natural
product synthesis, the requisite C(3a)–C(3a) relationship is
forged with excellent levels of diastereocontrol [entries 1–7, 13
to 50:1 diastereomeric ratio (dr)]. The electronic nature of the
,-unsaturated aldehyde component also appears to have a
broad scope. For example, the reaction can accommodate
enals that do not readily participate in iminium formation
(entry 1, R  COPh, 92% yield, 94% ee) and aldehydes that
provide stable iminium intermediates (entry 2, R  CH2OBz,
66% yield, 91% ee). Although the combination of CH2Cl2 and
H2O provides the optimal reaction medium for acrolein-
derived pyrroloindoline formation (Tables 1 and 2), the use of
dry CH2Cl2 was found to enhance enantioinduction in the
addition to -substituted ,-unsaturated aldehydes (Table 3).
This amine-catalyzed tryptamine addition–cyclization is also
general with respect to indole architecture (Table 3). Incorpo-
ration of alkyl and alkoxy substituents at the C(5)-indole position
reveals that electronic and steric modification of the indole ring
can be accomplished with little influence on reaction selectivity
(entries 4 and 5, 90% yield, 90–92% ee, 10 to 50:1 dr). As
revealed in entry 6, we have successfully used electron-deficient
nucleophiles in the context of a 6-bromo-substituted tryptamine
(86% yield, 97% ee, 31:1 dr). Such halogenated indole adducts
should prove to be valuable synthons for use in conjunction with
organometallic technologies [e.g., Buchwald–Hartwig (55, 56)
and Stille couplings (57)]. The capacity of 6-bromotryptamine
derivatives to participate in this process has direct implications
for the synthesis of 6-bromopyrroloindoline natural products
such as flustramine B (see below).
Furanoindoline Construction. Having successfully demonstrated
the capacity of iminium catalysis to rapidly build complex
pyrroloindoline systems, we sought to advance this enantiose-
lective addition–cyclization technology to the realm of furanoin-
doline architecture. This oxygen-containing tricyclic synthon is
also widely represented among natural isolates of biological
relevance, including diazonamide A (58), physovenine (59), and
picrinine (60). Given their structural similarity to the pyrroloin-
dolines, we envisioned that a wide array of furanoindolines might
be rapidly generated in enantioenriched format by the imple-
mentation of tryptaphol derivatives in this organocatalytic ad-
dition–cyclization sequence (Scheme 5).
As demonstrated in Schemes 6 and 7, preliminary studies have
demonstrated that the catalytic construction of furanoindolines
Table 2. Enantioselective pyrroloindoline formation with representative N(1)- and
N(10)-substituted tryptamines
Entry R1 R2 Time, h Yield, % ee,* %
1 Allyl t-Bu 25 85 89
2 Allyl Et 26 89 89
3 Prenyl Et 24 89 89
4 Benzyl Allyl 48 83 89
5 Benzyl t-Bu 30 82 90†
*Product ratios determined by HPLC.
†Absolute configuration determined by chemical correlation.
Table 3. Enantioselective pyrroloindoline formation with representative unsaturated
aldehydes and indoles
Entry R1 R2 Time, h Yield, % ee,* % dr†
1 H COPh 64 92 94 13:1
2 H CH2OBz 44 66 91 22:1
3 H CO2Me 28 93 91 44:1‡
4 5-Me CO2Me 18 94 92 50:1
5 5-MeO CO2Me 20 99 90 10:1
6 6-Br CO2Me 36 86 97 31:1
7 7-Me CO2Me 30 97 99 17:1
*Product ratios determined by chiral HPLC.
†dr, diastereomeric ratio.
‡Absolute configuration determined by x-ray crystallography.
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can also be realized with valuable levels of enantioinduction.
Exposure of N-benzyltryptophol to t-butyl-4-oxobutenoate in
the presence of amine catalyst 1d results in the production of the
desired tricycle in 93% ee and 80% yield (Scheme 6). Moreover,
the generation of the C(3a)–C(3a) stereochemical relationship
is accomplished with high fidelity (12:1 dr), in accord with the
analogous pyrroloindoline system. We have also found that
3-phenol-substituted indoles readily participate in this organo-
catalytic cascade sequence, thereby providing the basic furanoin-
doline core of the diazonamide family with excellent enantio-
selectivity (Scheme 7; 90% yield, 82% ee).
Natural Product Synthesis. The f lustramines (34, 40, 61) and
f lustramides (62) are a small family of marine alkaloids
isolated from the Bryozoa Flusta foliacea (L.). First described
in the late 1970s, this alkaloid family has yet to undergo broad
biological investigation; however, both f lustramines A and B
have been shown to block voltage-activated potassium chan-
nels (63) and exhibit skeletal and smooth muscle relaxant
properties (64). An architectural survey of the f lustramine
class reveals they are a structurally unique subgroup of the
pyrroloindoline isolate class because of the incorporation of a
(C6)-bromine substituent on the indoline ring system. Al-
though among the least complex of the pyrroloindoline natural
products, the f lustramines have not received broad synthetic
attention. Indeed, at the present time, only two syntheses (65,
66) of f lustramine B have been reported, both in racemic form.
Given that the f lustramine skeleton might represent an inter-
esting template for a medicinal or diversity-oriented chemistry
evaluation, we were prompted to undertake the enantioselec-
tive construction of f lustramine B. As a prominent design
feature, we sought to enantioselectively construct the central
bromo-tricyclic ring system in one chemical step by using our
organocatalytic pyrroloindoline technology.
Our synthesis began with the exposure of the 6-bromo-
tryptamine derivative 13 to acrolein in the presence of the
imidazolidinone catalyst 1d (Fig. 4). To our delight, the key
addition–cyclization cascade proceeded, as expected, to provide
the central f lustramine ring system 14 in 90% ee and 78% yield
after reduction of the resulting formyl group. Conversion of the
resulting C(3a)-3-hydroxy propyl adduct to the corresponding
C(3a)-allyl pyrroloindoline 15 was accomplished cleanly in a
three-step, two-pot sequence involving mesyl group formation–
displacement, followed by peroxide-mediated selenoxide elimi-
nation to generate the requisite terminal olefin in 89% yield.
Conversion of the resulting terminal allyl substituent to the
requisite prenyl group was accomplished in high efficiency by
exposure of 15 to 2-methyl-2-butene in the presence of Grubbs
second-generation metathesis catalyst. The decision to use an
allyl substituent as a synthetic precursor to a prenyl moiety was
predicated on the elegant studies of Grubbs and coworkers (67)
and Spessard and Stoltz (68). At this point, we envisioned that
the requisite conversion of the N-BOC system to N-Me could be
accomplished in one step by hydride reduction. Unfortunately,
however, exposure of the bisprenylated adduct 16 to lithium
aluminum hydride resulted in both carbamate reduction and
dehalogenation, thereby providing the known isolate debro-
moflustramine B in 91% yield. This dehalogenation pathway was
readily circumvented by selective removal of the BOC-protecting
group from 16 followed by reductive N-methylation of the
resulting pyrrolidine to afford ()-f lustramine B as a white
crystalline solid in 89% yield for the two-step process. Flustra-
mine B was found to be identical in all respects with the natural
isolate (61).
In summary, we have further established lowest unoccupied
molecular orbital-lowering organocatalysis as a broadly useful
concept for asymmetric synthesis in the context of pyrroloindo-
line construction. The rapid construction of this quaternary
carbon architecture has potential uses in medicinal chemistry,
natural product, and diversity-oriented synthesis. In this vein, we
have used this organocatalytic technology toward the enantio-
selective synthesis of ()-f lustramine B. Application of this
methodology to a variety of other pyrroloindoline and furanoin-
doline containing natural isolates is now under way.
Scheme 5.
Scheme 6.
Scheme 7.
Fig. 4. Total synthesis of ()-flustramine B
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